Drozitumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Drozitumab
Monoclonal antibody
Type Whole antibody
Source Human
Target DR5
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Formula C6334H9792N1700O2000S42
Molar mass 143.1 kg/mol
 NYesY (what is this?)  (verify)

Drozitumab is a human monoclonal antibody in development for the treatment of cancers.[1] It targets Tumour Necrosis Factor Related Apoptosis-inducing Ligand (TRAIL), whose receptors are found on the surface of many types of malignant cells.[2] Drozitumab was developed by Genentech.

Although drozitumab was studied in phase II trials for treating chondrosarcoma, colorectal cancer, non-Hodgkin lymphoma, and non-small cell lung cancer, development has been halted due to lack of clinical response.[2]

References[edit]

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Drozitumab" (PDF). American Medical Association. 
  2. ^ a b "Drozitumab". AdisInsight. Retrieved 31 January 2017.